A case report of successful therapy with tenofovir for a multi-drug resistant chronic hepatitis B patient complicated with malignant lymphoma

DOI Web Site Web Site 28 References
  • Watanabe Tsunamasa
    Department of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences
  • Sugauchi Fuminaka
    Department of Gastroenterology, Nagoya City Koseiin Medcial Welfare Center
  • Kusumoto Shigeru
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences
  • Shinkai Noboru
    Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences
  • Iio Etsuko
    Department of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences
  • Matsuura Kentarou
    Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences
  • Kusakabe Atsunori
    Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences
  • Miyaki Tomokatsu
    Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences
  • Nojiri Syunsuke
    Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences
  • Tanaka Yasuhito
    Department of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences

Bibliographic Information

Other Title
  • 多剤耐性変異を認めた悪性リンパ腫合併Ｂ型慢性肝炎に対しテノフォビルが著効した一例
  • 症例報告 多剤耐性変異を認めた悪性リンパ腫合併B型慢性肝炎に対しテノフォビルが著効した一例
  • ショウレイ ホウコク タザイ タイセイ ヘンイ オ ミトメタ アクセイ リンパ シュ ガッペイ Bガタ マンセイ カンエン ニ タイシ テノフォビル ガ チョコウシタ イチレイ

Search this article

Abstract

A 33-year-old man who diagnosed with malignant lymphoma was treated with lamivudine (LVD) for chronic hepatitis B in 2001. Because he experienced the first breakthrough hepatitis in 2005, adefovir (ADV) was added to the LVD regimen for dual therapy. In September 2007, LVD plus ADV combination therapy was replaced by entecavir (ETV) monotherapy. Eight months later, in May 2008, hepatitis B virus (HBV) DNA level elevated, followed by the second breakthrough hepatitis. After then, switching from ETV to LVD plus ADV could not suppress HBV-DNA level and ALT flare because sequencing analysis showed the evidence of multiple drug resistance with L80I, L180M, A181T, T184I and M204I/V mutations. In this case, after getting the approval of the ethical committee, we applied him the combination therapy with LVD and tenofovir (TDF), that decreased the serum HBV DNA and ALT concentration within a few months and obtained the complete remission of malignant lymphoma by allogenic bone marrow transplantation.<br>

Journal

  • Kanzo

    Kanzo 53 (1), 35-41, 2012

    The Japan Society of Hepatology

References(28)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top